Show simple item record

dc.contributor.authorLiu, Yinhui
dc.contributor.authorSong, Xiaobo
dc.contributor.authorZhou, Huimin
dc.contributor.authorZhou, Xue
dc.contributor.authorXia, Yunlong
dc.contributor.authorDong, Xin
dc.contributor.authorZhong, Wei
dc.contributor.authorTang, Shaoying
dc.contributor.authorWang, Lili
dc.contributor.authorWen, Shu
dc.contributor.authorXiao, Jing
dc.contributor.authorTang, Li
dc.date.accessioned2019-02-25T09:39:48Z
dc.date.available2019-02-25T09:39:48Z
dc.date.issued2018-03-22
dc.description.abstractBackground: Statin has been widely used to treat hyperlipidemia because of its high potency in decreasing cholesterol levels. The present study aimed to examine the lipid-lowering effect of rosuvastatin and the composition, diversity and species abundance of gut microbiome in association with rosuvastatin efficacy. <br> <br> TRIAL REGISTRATION: ChiCTR-ORC-17013212 at the First Affiliated Hospital of Dalian Medical University, November 2, 2017. Results:Totally 64 patients with hyperlipidemia were treated with 10 mg/day of rosuvastatin for 4-8 weeks. Blood lipid indicators triglycerides (TG), total cholesterol (TC), high density lipoprotein (HDL), low-density lipoprotein cholesterol (LDL-C) were measured before and after the treatment. Stool samples were collected right after the treatment. Following total DNA extraction and PCR amplification of 16S rRNA gene, Illumina sequencing was performed for gut microbiome identification, classification and characterization. All the patients showed a significant blood lipid reduction after the treatment. The patients were grouped according to parallel manner design. Group I had 33 patients whose blood lipid levels dropped to the normal levels from week 4, with 58.5% reduction in LDL-C and 26.6% reduction in TC. Group II had 31 patients whose blood lipid levels were still above the normal levels after 8 weeks therapy, but with 41.9% reduction in LDL-C and 31.2% reduction in TC. Based on Operational Taxonomic Unit data, Alpha-diversity by Shannon Index was different between the two groups, and beta-diversity by Principle Component Analysis exhibited separated patterns of the two groups. The differences were also observed in the relative-abundance at phylum, family, and genus levels of the two groups. Linear discriminate analysis illustrated that the abundance of 29 taxa was higher in group I, while the abundance of other 13 taxa was higher in group II. Phyla Firmicutes and Fusobacteria had negative correlation to LDL-C level, but Cyanobacteria and Lentisphaerae had a positive correlation to LDL-C level. Moreover, gender and age were also found somehow correlated to microbial community composition. Conclusion: Rosuvastatin therapy had different blood lipid-lowering effect on hyperlipidemia. The gut microbiota exhibited variation in community composition, diversity and taxa in association to rosuvastatin hypolipidemic effect. These results indicate that modulation of gut microflora, especially the negative/positive correlated species might strengthen statin efficacy in statin-inadequate patients.en_US
dc.descriptionSource at <a href= https://doi.org/10.3389/fmicb.2018.00530> https://doi.org/10.3389/fmicb.2018.00530 </a>.en_US
dc.identifier.citationLiu, Y., Song, X., Zhou, H., Zhou, X., Xia, Y., Dong, X., …Tang, L. (2018). Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo. Frontiers in Microbiology, 9,530. https://doi.org/10.3389/fmicb.2018.00530 .en_US
dc.identifier.cristinIDFRIDAID 1585924
dc.identifier.doi10.3389/fmicb.2018.00530
dc.identifier.issn1664-302X
dc.identifier.urihttps://hdl.handle.net/10037/14757
dc.language.isoengen_US
dc.publisherFrontiers Mediaen_US
dc.relation.journalFrontiers in Microbiology
dc.rights.accessRightsopenAccessen_US
dc.subjectGut microbiomeen_US
dc.subject16S rRNA sequencingen_US
dc.subjectRosuvastatinen_US
dc.subjectHyperlipidemiaen_US
dc.subjectHypolipidemic effecten_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Cardiology: 771en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Kardiologi: 771en_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Medical microbiology: 715en_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk mikrobiologi: 715en_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Pharmacology: 728en_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Farmakologi: 728en_US
dc.titleGut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivoen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record